Nivolumab as a safe and effective treatment in an HIV patient with refractory Hodgkin lymphoma

被引：7
|
作者：
Serrao, Alessandra [1 ]
Canichella, Martina [1 ]
De Luca, Maria Lucia [1 ]
Tartaglia, Germana [1 ]
Annechini, Giorgia [1 ]
D'Elia, Gianna Maria [1 ]
Pulsoni, Alessandro [1 ]
机构：
[1] Sapienza Univ Rome, Dept Cellular Biotecnol & Hemathol, Via Benevento 6, I-00161 Rome, Italy
来源：
ANNALS OF HEMATOLOGY | 2019年 / 98卷 / 06期
关键词：
STEM-CELL TRANSPLANTATION; BRENTUXIMAB VEDOTIN; MULTICENTER;
D O I：
10.1007/s00277-018-3541-0
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1505 / 1506
页数：2
相关论文
共 50 条
  • [1] Nivolumab as a safe and effective treatment in an HIV patient with refractory Hodgkin lymphoma
    Alessandra Serrao
    Martina Canichella
    Maria Lucia De Luca
    Germana Tartaglia
    Giorgia Annechini
    Gianna Maria D’Elia
    Alessandro Pulsoni
    Annals of Hematology, 2019, 98 : 1505 - 1506
  • [2] Nivolumab experience in a patient with refractory Hodgkin lymphoma
    Karaman, S.
    Tugcu, D.
    Aydogdu, S.
    Karagenc, A.
    Dogan, O.
    Turkmen, A.
    Ocak, S.
    Tuna, R.
    Karakas, Z.
    LEUKEMIA RESEARCH, 2018, 73 : S65 - S65
  • [3] Nivolumab in the Treatment of Refractory Pediatric Hodgkin Lymphoma
    Foran, Alexandra E.
    Nadel, Helen R.
    Lee, Anna F.
    Savage, Kerry J.
    Deyell, Rebecca J.
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2017, 39 (05) : E263 - E266
  • [4] Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy
    Sandoval-Sus, Jose D.
    Mogollon-Duffo, Francis
    Patel, Ankita
    Visweshwar, Nathan
    Laber, Damian A.
    Kim, Richard
    Jagal, Michael V.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [5] Treatment of refractory Hodgkin lymphoma patients: the role of Nivolumab
    Faber, N.
    Menzel, H.
    Benk, J.
    Lukic, S.
    Drewniock, P.
    Sitskaya, X.
    Basara, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 319 - 319
  • [6] Repeated courses of escalating doses of Nivolumab in refractory Hodgkin lymphoma with recurrent relapses post allografting: A safe and effective treatment approach
    Kaloyannidis, Panayotis
    Al Shaibani, Eshrak
    Moinnudin, Asif
    Al Anezi, Khalid
    Al Hashmi, Hani
    HEMATOLOGY REPORTS, 2021, 13 (01)
  • [7] Nivolumab plus Brentuximab vedotin plus /- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma
    Greve, Patrick
    Beishuizen, Auke
    Hagleitner, Melanie
    Loeffen, Jan
    Veening, Margreet
    Boes, Marianne
    Peperzak, Victor
    Diez, Claudius
    Meyer-Wentrup, Friederike
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [8] Nivolumab Induced Seronegative Arthritis in a Patient With Refractory Hodgkin's Lymphoma
    Colak, Seda
    Omma, Ahmet
    ARCHIVES OF RHEUMATOLOGY, 2019, 34 (01) : 112 - 114
  • [9] Nivolumab in the Treatment of Hodgkin Lymphoma
    Ansell, Stephen M.
    CLINICAL CANCER RESEARCH, 2017, 23 (07) : 1623 - 1626
  • [10] Nivolumab in relapsed/refractory Hodgkin lymphoma: towards a new treatment strategy?
    Cencini, Emanuele
    Bocchia, Monica
    Fabbri, Alberto
    AMERICAN JOURNAL OF BLOOD RESEARCH, 2021, 11 (03): : 261 - 265
12345